🏢 What kind of company is Coherus Oncology?

Coherus Oncology (CHRS) is a US-headquartered biotech company focused on immuno-oncology. It started out with a biosimilar-centric business, but recently divested the UDENYCA franchise to Intas Pharmaceuticals and restructured into a specialist in immuno-oncology therapeutics.

Its core product is LOQTORZI (toripalimab), the approved nasopharyngeal cancer treatment in the United States, and the company is expanding its immuno-oncology pipeline around this asset. It is classified as a small, single-therapeutic-area oncology-focused biotech.

How does Coherus Oncology make money?

Recent revenue is generated through the nasopharyngeal cancer treatment LOQTORZI, and double-digit sequential quarterly growth has continued. The divestiture of the UDENYCA franchise removed legacy biosimilar revenue, shifting the business's center of gravity toward immuno-oncology. Clinical-stage pipeline assets do not yet contribute to revenue, and the company shows the typical loss profile of a small biotech with heavy R&D investment. Areas with limited data availability need to be assessed on a qualitative basis.

📐 Coherus Oncology market cap and company scale

The market capitalization is $205.5M, and the employee count is 147 people.

As a small, oncology-focused biotech, its scale is reflected by a single approved product and an early-stage clinical pipeline. Its market cap is modest compared with larger biotech peers, and the gap in business scale versus major players such as PFE is substantial. Capital allocation follows a growth-oriented policy that prioritizes reinvestment in R&D over dividends.

In the near term, the key variables are the revenue growth pace of LOQTORZI in nasopharyngeal cancer and its positioning within treatment guidelines. Over the medium to long term, clinical readouts from immuno-oncology pipeline assets — such as the IL-27 antagonist casdozokitug and chemokine receptor-targeting antibodies — will determine corporate value. However, high single-product concentration, pipeline clinical failure risk, the potential need for additional financing, and intensifying competition with large pharma all serve as sources of potential volatility.

• LOQTORZI revenue expansion and strengthening of indication positioning
• Clinical progress of the immuno-oncology pipeline
• Cost efficiency improvement from simplified business structure

⚔️ Coherus Oncology key strengths and risks

Focus on immuno-oncology and possession of an approved product are strengths, while single-product dependence and clinical/funding risks are core weaknesses.

🔄 Coherus Oncology competitors and related stocks (beneficiaries)

Direct competitors often compared within the oncology biotech space include oncology therapeutics developer EXEL and cellular/immuno-oncology therapy developer IOVA. Related names commonly grouped with CHRS include large-cap pharma MRK, a leader in immuno-oncology, and PFE, which is expanding its oncology portfolio. Shifts in these majors' immuno-oncology strategies influence the competitive environment for small oncology biotechs such as CHRS.

✅ Coherus Oncology investor checklist

Key points to monitor when evaluating Coherus Oncology. The revenue growth pace of LOQTORZI in nasopharyngeal cancer, the clinical timeline of the immuno-oncology pipeline, and the cash burn rate and financing capacity all serve as core short- to medium-term variables. | Checkpoint | What to Check | Current Status | |---|---|---| | LOQTORZI Revenue | Quarterly revenue growth trajectory of the nasopharyngeal cancer treatment | Growth trend | | Pipeline | Clinical-stage progress of immuno-oncology candidates | Early stage | | Cash Position | Cash burn rate and funding requirements | Watch closely | | Profitability | R&D intensity and profit-loss structure | Investment-heavy phase | Given the high single-product concentration, any slowdown in LOQTORZI revenue would translate into a significant earnings shock. Clinical-stage pipeline failure risk, potential equity dilution from additional financing, and intensifying competition with large pharma are also core risk factors.

Having restructured from biosimilars to immuno-oncology, Coherus Oncology is a small, oncology-focused biotech whose approved product LOQTORZI and immuno-oncology pipeline form its core value pillars. Given the high volatility typical of early-stage biotechs, a staggered buying approach with a long-term horizon is recommended.

⚔️ Coherus Oncology key strengths and risks

Focus on immuno-oncology and possession of an approved product are strengths, while single-product dependence and clinical/funding risks are core weaknesses.

🔄 Coherus Oncology competitors and related stocks (beneficiaries)

Direct competitors often compared within the oncology biotech space include oncology therapeutics developer EXEL and cellular/immuno-oncology therapy developer IOVA. Related names commonly grouped with CHRS include large-cap pharma MRK, a leader in immuno-oncology, and PFE, which is expanding its oncology portfolio. Shifts in these majors' immuno-oncology strategies influence the competitive environment for small oncology biotechs such as CHRS.

✅ Coherus Oncology investor checklist

Key points to monitor when evaluating Coherus Oncology. The revenue growth pace of LOQTORZI in nasopharyngeal cancer, the clinical timeline of the immuno-oncology pipeline, and the cash burn rate and financing capacity all serve as core short- to medium-term variables. | Checkpoint | What to Check | Current Status | |---|---|---| | LOQTORZI Revenue | Quarterly revenue growth trajectory of the nasopharyngeal cancer treatment | Growth trend | | Pipeline | Clinical-stage progress of immuno-oncology candidates | Early stage | | Cash Position | Cash burn rate and funding requirements | Watch closely | | Profitability | R&D intensity and profit-loss structure | Investment-heavy phase | Given the high single-product concentration, any slowdown in LOQTORZI revenue would translate into a significant earnings shock. Clinical-stage pipeline failure risk, potential equity dilution from additional financing, and intensifying competition with large pharma are also core risk factors.

Having restructured from biosimilars to immuno-oncology, Coherus Oncology is a small, oncology-focused biotech whose approved product LOQTORZI and immuno-oncology pipeline form its core value pillars. Given the high volatility typical of early-stage biotechs, a staggered buying approach with a long-term horizon is recommended.